Filed Pursuant to Rule 424(b)(3)
 Registration No. 333-260528
Prospectus Supplement No. 5
(to prospectus dated March 11, 2022)
![](https://content.edgar-online.com/edgar_conv_img/2022/09/19/0000950103-22-015982_image_001.jpg)
Mirion Technologies, Inc.
Up to 8,560,540 Shares of our Class A
Common Stock Issuable upon Redemption of Shares of IntermediateCo Class B Common Stock
Up to 27,249,979 Shares of our Class A Common Stock Issuable upon Exercise of Warrants
143,250,440 Shares of our Class A Common Stock for Resale by the Selling Holders
This prospectus supplement
is being filed to update and supplement the information contained in the prospectus dated March 11, 2022 (the “Prospectus”),
which forms part of our registration statement on Form S-1 (No. 333-260528) with the information contained in our Current Report on Form
8-K, filed with the Securities and Exchange Commission (the “SEC”) on September 19, 2022 (the “Current Report”).
Accordingly, we have attached the Current Report to this prospectus supplement.
The Prospectus and this prospectus supplement relate
to: (1) the issuance by us of up to an aggregate of 35,810,519 shares of Class A common stock, par value $0.0001 per share (“Class A
common stock”), of Mirion Technologies, Inc. (the “Company”) that may be issued upon (i) the exercise of 27,249,979
warrants to purchase Class A common stock at an exercise price of $11.50 per share of Class A common stock, including the public
warrants and the private placement warrants (each as defined in the Prospectus), and (ii) the redemption of up to 8,560,540 shares
of Class B common stock, par value $0.0001 per share (the “IntermediateCo Class B common stock”), of Mirion IntermediateCo,
Inc. (“IntermediateCo”); and (2) the offer and sale, from time to time, by the selling holders identified in the Prospectus
(the “Selling Holders”), or their permitted transferees, of up to 143,250,440 shares of Class A common stock.
This prospectus supplement updates and supplements
the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus,
including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there
is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this
prospectus supplement. Terms used in this prospectus supplement but not defined herein shall have the meanings given to such terms in
the Prospectus.
You should read the Prospectus, this prospectus
supplement and any additional prospectus supplement or amendment carefully before you invest in our securities. Our Class A common stock
and public warrants are listed on the New York Stock Exchange under the symbols “MIR” and “MIR WS,” respectively.
On September 16, 2022, the closing price of our Class A common stock was $7.45 per share and the closing price for our public warrants
was $1.54 per warrant.
Investing in our Class A common stock and warrants
involves a high degree of risk. See the section titled “Risk Factors” beginning on page 19 of the Prospectus and in any applicable
prospectus supplement.
Neither the SEC nor any other state securities
commission has approved or disapproved of these securities or passed on the adequacy or accuracy of the Prospectus or this prospectus
supplement. Any representation to the contrary is a criminal offense.
September 19, 2022
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (date of earliest event reported): September 13, 2022
Mirion
Technologies, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware |
001-39352 |
83-0974996 |
(State
or Incorporation) |
(Commission
File Number) |
(I.R.S.
Employer Identification Number) |
|
|
|
|
1218
Menlo Drive |
|
|
Atlanta,
Georgia 30318 |
|
|
(Address
of Principal Executive Offices) |
|
|
|
|
|
(770)
432-2744 |
|
|
(Registrant's
telephone number, including area code) |
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
Class
A common stock, $0.0001 par value per share |
|
MIR |
|
New
York Stock Exchange |
Redeemable
warrants to purchase Class A common stock |
|
MIR
WS |
|
New
York Stock Exchange |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Departure
of Christopher Warren from the Board of Directors
On
September 13, 2022, Christopher Warren, a member of the board of directors (the Board) of Mirion Technologies, Inc. (the “Company”), notified
the Company of his intent to resign from the Board, effective at the close of business on September 16, 2022. Mr. Warren’s departure from
the Board is not due to any disagreement with the Company or the Board on any matter relating to the operations, policies or practices
of the Company.
Appointment
of Sheila Rege to the Board of Directors
On
September 13, 2022, Christopher Warren, a member of the board of directors (the Board) of Mirion Technologies, Inc. (the “Company”), notified
the Company of his intent to resign from the Board, effective at the close of business on September 16, 2022. Mr. Warren’s departure from
the Board is not due to any disagreement with the Company or the Board on any matter relating to the operations, policies or practices
of the Company.
On
September 16, 2022, after recommendation by the Nominating and Corporate Governance Committee of the Board, the Board appointed Ms. Sheila
Rege, M.D., as a member of the Board, effective immediately, to fill the vacancy created by Mr. Warren’s resignation. Dr. Rege will stand
for reelection as a member of the Board at the Company’s 2023 annual meeting of stockholders. Dr. Rege was also appointed to serve as
a member of the Audit Committee and the Compensation Committee of the Board.
Dr.
Rege is a board-certified radiation oncologist and the Chief Executive Officer and Founder of Northwest Cancer Clinic, a provider of
radiation oncology and nuclear medicine services, which opened in 2012. Dr. Rege joins the Mirion team with over 30 years of experience
in the field of nuclear medicine and radiation oncology. From 2007 to 2019 Dr. Rege served on the board of directors of Physicians Insurance,
a mutual company, serving as the Chair of the Nominating Committee and a member of the Compensation, Executive and CEO Succession Committee.
Dr. Rege is the recipient of numerous awards and accolades including the American Medical Association Women Physician Section Inspiration
Award in 2021, the Private Company Boardroom “2022 Directors to Watch,” The American College of Radiation Oncology 2022 Sucha Asbell Mentorship
Award, and has been recognized as a “Top Oncologist” by Consumer Research Council of America in 2012. Dr. Rege received her B.A. from the
University of California, Berkeley, and her M.D. from the University of California, Los Angeles.
Dr.
Rege will receive the Company's standard compensation for non-employee directors in accordance with the Company's Non-Employee Director
Compensation Policy, as described in the Company's proxy statement filed with the Securities and Exchange Commission on April 20, 2022.
Dr. Rege will execute an indemnification agreement consistent with the Company’s standard form of indemnification agreement, filed as
an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
There
is no arrangement or understanding between Dr. Rege and any other persons pursuant to which Dr. Rege was appointed as a director, and,
other than as set forth above, Dr. Rege has no direct or indirect material interest in any transaction required to be disclosed under
Item 404(a) of Regulation S-K.
Item 7.01.
Regulation FD Disclosure.
On
September 19, 2022, the Company issued a press release regarding the appointment of Dr. Rege and the departure of Mr. Warren. The full
text of the press release is furnished as Exhibit 99.1 hereto. The information in Exhibit 99.1 hereto is intended to be furnished and
shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
EXHIBIT
INDEX
* Filed herewith.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: September
19, 2022
|
Mirion
Technologies, Inc. |
|
|
|
By: |
/s/ Brian
Schopfer |
|
Name: |
Brian Schopfer |
|
Title: |
Chief Financial Officer |
News Release |
|
![mirion.jpg](https://content.edgar-online.com/edgar_conv_img/2022/09/19/0000950103-22-015982_image_003.jpg) |
Mirion Technologies Appoints Dr. Sheila Rege,
M.D. to Board of Directors, Replacing Mr. Christopher Warren
Atlanta, GA – September
19, 2022 – Mirion Technologies, Inc. (“Mirion,” “we” or the “Company”) (NYSE: MIR), a
global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and
research end markets, today announced that Dr. Sheila Rege, M.D. has been appointed to the Board of Directors, replacing Mr.
Christopher Warren, who is stepping down.
Lawrence D. Kingsley, Chairman of Mirion’s
Board of Directors said, “I am pleased to welcome Sheila to Mirion’s Board of Directors. She brings deep experience and a long track record
of accomplishment in nuclear medicine and radiation oncology to Mirion’s Board. We are excited to have Sheila join us and believe that
her diverse skill set and voice will be invaluable as Mirion aims to grow its Medical segment to at least 50% of total company revenue
over time.”
“It is a great honor to have been appointed
to Mirion’s Board of Directors,” said Dr. Rege. “I am a strong believer in Mirion’s mission and feel that the Company has strong growth prospects,
especially within the Medical segment. I am excited to begin working alongside my fellow Board members and the management team to contribute
to the Company’s future success.”
Dr. Rege is a board-certified radiation
oncologist and the Founder and Chief Executive Officer of Northwest Cancer Clinic, a provider of radiation oncology and nuclear medicine
services, which opened in 2012. Dr. Rege joins Mirion’s Board of Directors with over 30 years of experience in the field of nuclear medicine
and radiation oncology. From 2007 to 2019, Dr. Rege sat on the Board of Directors of Physicians Insurance, serving as the Chair of the
Nominating Committee and a member of the Compensation, Executive and CEO Succession Committees. Dr. Rege is the recipient of numerous
awards and accolades including the American Medical Association Women Physician Section Inspiration Award in 2021, the Private Company
Boardroom 2022 “Directors to Watch”, The American College of Radiation Oncology 2022 Sucha Asbell Mentorship Award, and has been recognized
as a “Top Oncologist” by the Consumer Research Council of America in 2012. Dr. Rege received her B.A. from the University of California,
Berkeley, and her M.D. from the University of California, Los Angeles.
“I would also like to thank Chris Warren
for all of his contributions to Mirion’s Board,” continued Mr. Kingsley. “Chris and the Charterhouse team have been an incredibly supportive
partner, playing a key role in Mirion’s growth journey since their initial investment in 2015. We wish Chris all the best in his future
endeavors.”
Chris Warren stated, “I leave Mirion’s
Board with a great deal of pride in the work we have been able to accomplish together. Since Charterhouse first acquired Mirion in 2015,
the Company has undergone a strategic evolution through the expansion of its Medical segment, while delivering strong growth. I exit
the Board at a point in Mirion’s history when the Company is experiencing strong order and demand momentum, supported by healthy and robust
end markets. I believe the Company is in tremendous hands and am excited to see what the team will accomplish in the years to come.”
About Mirion
Mirion Technologies is a leading
provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets. The
organization aims to harness its unrivaled knowledge of ionizing radiation for the greater good of humanity. Headquartered in
Atlanta (GA – USA), Mirion employs around 2,800 people and operates in 13 countries. For more information, and for the latest
news and content from Mirion, visit ir.mirion.com.
News Release |
|
![mirion.jpg](https://content.edgar-online.com/edgar_conv_img/2022/09/19/0000950103-22-015982_image_003.jpg) |
Contacts:
For investor inquiries:
Jerry Estes
ir@mirion.com
For media inquiries:
Matthew Maddox
mmaddox@mirion.com
Mirion Technologies (NYSE:MIR)
Historical Stock Chart
From May 2024 to Jun 2024
Mirion Technologies (NYSE:MIR)
Historical Stock Chart
From Jun 2023 to Jun 2024